Relationship between hyperglycemia and infection in critically ill patients.
Hyperglycemia is a common problem encountered in hospitalized patients, especially in critically ill patients and those with diabetes mellitus. Uncontrolled hyperglycemia may be associated with complications such as fluid and electrolyte disturbances and increased infection risk. Studies have demonstrated impairment of host defenses, including decreased polymorphonuclear leukocyte mobilization, chemotaxis, and phagocytic activity related to hyperglycemia. Until 2001, hyperglycemia (blood glucose concentrations up to 220 mg/dl) had been tolerated in critically ill patients not only because high blood glucose concentrations were believed to be a normal physiologic reaction in stressed patients and excess glucose is necessary to support the energy needs of glucose-dependent organs, but also because the true significance of short-term hyperglycemia was not known. Recent clinical data show that the use of intensive insulin therapy to maintain tight blood glucose concentrations between 80 and 110 mg/dl decreases morbidity and mortality in critically ill surgical patients. Intensive insulin therapy minimizes derangements in normal host defense mechanisms and modulates release of inflammatory mediators. The principal benefit of intensive insulin therapy is a decrease in infection-related complications and mortality. Further research will define which patient populations will benefit most from intensive insulin therapy and firmly establish the blood glucose concentration at which benefits will be realized.
Butler
Simona O
SO
Department of Pharmacy Services, University of Michigan Hospitals and Health Centers, Ann Arbour, Michigan 48109, USA.
Btaiche
Imad F
IF
Alaniz
Cesar
C
D002986:Clinical Trials as Topic; D016638:Critical Illness; D003428:Cross Infection / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control; D048909:Diabetes Complications / Q000276:immunology / Q000517:prevention & control; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006943:Hyperglycemia / Q000150:complications* / Q000276:immunology / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D010288:Parenteral Nutrition; D011183:Postoperative Complications / Q000276:immunology / Q000517:prevention & control; D012306:Risk
D007004:Hypoglycemic Agents; D007328:Insulin; D005947:Glucose